20002016
If you made any changes in Pure these will be visible here soon.

Personal profile

Biography

Karen is a Research Fellow in the Faculty of Business and Economics at Monash University. She has over ten years of experience evaluating the clinical- and cost-effectiveness of medical technologies for funding on national insurance schemes.  This includes the development of modelled economic evaluations as well as reviews of funded technologies to ensure continued value for money.  Her work has directly informed recommendations by the Pharmaceutical Benefits Advisory Committee (PBAC) and the Medical Services Advisory Committee (MSAC) in Australia, and the Agency for Care Effectiveness (ACE) in Singapore. 

Other research interests include economic modelling, funding decisions by health technology assessment committees, including using drug reimbursement data in Australia.

Research area keywords

  • Economic modelling
  • Pharmaceuticals
  • Cost Utility Analysis

Research Output 2000 2016

5 Citations (Scopus)

What can we expect from value-based funding of medicines? A retrospective study

Harris, A. H., Li, J. J. & Yong, K. K. L., 2016, In : PharmacoEconomics. 34, 4, p. 393 - 402 10 p.

Research output: Contribution to journalArticleResearchpeer-review

228 Citations (Scopus)

Using effectiveness and cost-effectiveness to make drug coverage decisions: A comparison of Britain, Australia, and Canada

Clement, F., Harris, A. H., Li, J. J., Yong, K. K. L., Lee, K. & Manns, B., 2009, In : JAMA. 302, 13, p. 1437 - 1443 7 p.

Research output: Contribution to journalArticleResearchpeer-review

Relative influence of Quality of Life and survival in cost-utility analysis

Defina, J., Yong, K., Harris, A. & Kolivos, A., 2000, p. 17 - 29. 13 p.

Research output: Contribution to conferenceOtherOther